MWVC
CHRS icon

Morgens Waterfall Vintiadis & Co’s Coherus Oncology CHRS Stock Holding History

Morgens Waterfall Vintiadis & Co’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-50,000
Closed -$1.1M – 54
2019
Q2 		$1.1M Buy
+50,000
New +$868K 0.76% 35

Other funds holding CHRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Morgens Waterfall Vintiadis & Co's CHRS Position: Q3 2019 in Review

Morgens Waterfall Vintiadis & Co sold out of Coherus Oncology (CHRS) in Q3 2019, closing a stake of 50,000 shares — an estimated $1.1M sold.

Morgens Waterfall Vintiadis & Co first reported a position in CHRS in Q2 2019 and held it in 1 quarter. The position peaked at $1.1M in Q2 2019. 167 funds tracked by Wall St. Rank hold CHRS as of Q3 2019.

  • Morgens Waterfall Vintiadis & Co reported no remaining Coherus Oncology position as of Q3 2019 after selling out during the quarter.
  • Morgens Waterfall Vintiadis & Co sold 50,000 Coherus Oncology shares in Q3 2019, an estimated $1.1M.
  • Morgens Waterfall Vintiadis & Co first reported a position in Coherus Oncology in Q2 2019 and held it in 1 quarter.
  • Morgens Waterfall Vintiadis & Co's Coherus Oncology position peaked at $1.1M in Q2 2019.
  • 167 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2019.

Based on Morgens Waterfall Vintiadis & Co's 13F filing for Q3 2019, filed 14 Nov 2019.